Reactivity of human convalescent sera with influenza virus hemagglutinin protein mutants at antigenic site A

被引:11
作者
Nobusawa, Eri [1 ]
Omagari, Katsumi [1 ]
Nakajima, Setsuko [1 ]
Nakajima, Katsuhisa [1 ]
机构
[1] Nagoya City Univ, Grad Sch Med Sci, Dept Virol, Nagoya, Aichi, Japan
关键词
antigenic drift; hemagglutinin; human sera; AMINO-ACID CHANGE; A VIRUS; MONOCLONAL-ANTIBODIES; RECOGNITION; INFECTION; H3N2; MICE; NEURAMINIDASE; PROTECTION; EMERGENCE;
D O I
10.1111/j.1348-0421.2012.00412.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
How the antibodies of individual convalescent human sera bind to each amino acid residue at the antigenic sites of hemagglutinin (HA) of influenza viruses, and how the antigenic drift strains of influenza viruses are selected by human sera, is not well understood. In our previous study, it was found by a binding assay with a chimeric HA between A/Kamata/14/91 (Ka/91) and A/Aichi/2/68 that convalescent human sera, following Ka/91 like (H3N2) virus infection, bind to antigenic site A of Ka/91 HA. Here using chimeric HAs possessing single amino acid substitutions at site A, it was determined how those human sera recognize each amino acid residue at antigenic site A. It was found that the capacity of human sera to recognize amino acid substitutions at site A differs from one person to another and that some amino acid substitutions result in all convalescent human sera losing their binding capacity. Among these amino acid substitutions, certain ones might be selected by chance, thus creating successive antigenic drift. Phylogenetic analysis of the drift strains of Ka/91 showed amino acid substitutions at positions 133, 135 and 145 were on the main stream of the phylogenetic tree. Indeed, all of the investigated convalescent sera failed to recognize one of them.
引用
收藏
页码:99 / 106
页数:8
相关论文
共 21 条
[1]  
Arnold JJ, 2004, BIOCHEMISTRY-US, V43, P5126, DOI 10.1021/bi035212y
[2]   IMMUNITY TO INFLUENZA IN MAN [J].
COUCH, RB ;
KASEL, JA .
ANNUAL REVIEW OF MICROBIOLOGY, 1983, 37 :529-549
[3]   INACTIVATED INFLUENZA VACCINES .2. LABORATORY INDEXES OF PROTECTION [J].
DOWDLE, WR ;
COLEMAN, MT ;
MOSTOW, SR ;
KAYE, HS ;
SCHOENBAUM, SC .
POSTGRADUATE MEDICAL JOURNAL, 1973, 49 (569) :159-163
[4]  
EPSTEIN SL, 1993, J IMMUNOL, V150, P5484
[5]  
Fleury D, 2000, PROTEINS, V40, P572
[6]   Role of the B-cell response in recovery of mice from primary influenza virus infection [J].
Gerhard, W ;
Mozdzanowska, K ;
Furchner, M ;
Washko, G ;
Maiese, K .
IMMUNOLOGICAL REVIEWS, 1997, 159 :95-103
[7]   ROLE OF SERUM HEMAGGLUTINATION-INHIBITING ANTIBODY IN PROTECTION AGAINST CHALLENGE INFECTION WITH INFLUENZA A2 AND B VIRUSES [J].
HOBSON, D ;
CURRY, RL ;
BEARE, AS ;
WARDGARD.A .
JOURNAL OF HYGIENE, 1972, 70 (04) :767-777
[8]   THE STRUCTURE OF A COMPLEX BETWEEN THE NC10 ANTIBODY AND INFLUENZA-VIRUS NEURAMINIDASE AND COMPARISON WITH THE OVERLAPPING BINDING-SITE OF THE NC41 ANTIBODY [J].
MALBY, RL ;
TULIP, WR ;
HARLEY, VR ;
MCKIMMBRESCHKIN, JL ;
LAVER, WG ;
WEBSTER, RG ;
COLMAN, PM .
STRUCTURE, 1994, 2 (08) :733-746
[9]   Accumulation of amino acid substitutions promotes irreversible structural changes in the hemagglutinin of human influenza AH3 virus during evolution [J].
Nakajima, K ;
Nobusawa, E ;
Nagy, A ;
Nakajima, S .
JOURNAL OF VIROLOGY, 2005, 79 (10) :6472-6477
[10]   Restriction of amino acid change in influenza A virus H3HA: Comparison of amino acid changes observed in nature and in vitro [J].
Nakajima, K ;
Nobusawa, E ;
Tonegawa, K ;
Nakajima, S .
JOURNAL OF VIROLOGY, 2003, 77 (18) :10088-10098